Caring Beyond Prescriptions — Our Story, Mission, and Values

We go beyond just treating symptoms — we focus on understanding each patient’s unique health journey.

Dr. Amarinder Sandhu

Know About Your Doctor

Education and Training

  • MBBS (2014)
    SGRD Institute of Medical Sciences & Research, Amritsar, Punjab, India
    Field of Study: Medicine

  • DFM (2015)
    Royal College of General Practitioners, United Kingdom
    Field of Study: Family Medicine

  • DDM (2016)
    Martin Luther University, Meghalaya, India
    Field of Study: Diabetes Management

  • PGDID (2018)
    University of New South Wales, Australia
    Field of Study: Infectious Diseases

  • PGDMCH (2022)
    Indira Gandhi National Open University (IGNOU), New Delhi, India
    Field of Study: Maternal and Child Health

Research Articles / Publications

  • “Profound Hyponatremia: Prevalence, Underlying Disorders and Outcome in a Tertiary Care Hospital”
    British Journal of Medicine & Medical Research, Vol. 14, Issue 12, Pages 1–6, 2016
    Article No.: BJMMR.23971
    Authors: Parminder Singh, Amarinder Singh

Professional Memberships

International

  • ADA – American Diabetes Association

  • EASD – European Association for the Study of Diabetes

  • RCGP, UK – Royal College of General Practitioners

National

  • RSSDI – Research Society for the Study of Diabetes in India

  • IMA – Indian Medical Association

  • Diabetes & Endocrine Society, Punjab

Dr. Amarinder Singh

National Speaker Engagements

(CME Sessions – Virtual & In-Person)

Pharmaceutical-Sponsored Talks

  • “Role of Metoprolol in Managing IHD & HF Fluctuations” – CIPLA Ltd

  • “60 Years Journey of Metformin – A Glance at the Past and Future” – INTAS Pharmaceuticals

  • “Risk of Chronic Disease in the Current Pandemic: SGLT2-I Role in CV-Kidney-Metabolic Risk Control” – Boehringer Ingelheim (02/05/2021)

  • “Concomitant Use of OADs and Insulin in T2DM Management” – Sanofi India

  • “Dapagliflozin: A Cut Above the Rest among SGLT2 Inhibitors” – AstraZeneca

  • “DPP4i in T2DM: Focus on Vildagliptin SR Formulation” – CIPLA Ltd (23/11/2021)

  • “Metformin SR + Vildagliptin in Diabetes Management” – Dr. Reddy’s (27/12/2020)

  • “Is SGLT2i a Diabetes or Cardiovascular Drug?” – CIPLA Ltd (07/01/2021)

  • “Empagliflozin & Linagliptin Combination: Real World Case Studies” – Case Club Meeting

  • Sanofi Cardio Diabetes e-RTM (07/12/2021 & 18/12/2021 – Chaired the session)

  • “Post-Prandial Hyperglycemia Management with Voglibose & Repaglinide” – Sun Pharma Metabolic Meet (25/08/2021)

  • “Managing Heart Rate in Heart Failure: Why and How” – CIPLA Ltd

0 +

Years of Experience 

With over a decade of clinical experience, we bring trusted medical expertise to every patient we serve.
Our long-standing commitment to quality care ensures effective treatment and lasting health outcomes.

0 +

Patients

We’ve successfully treated over 2,500 patients with personalized care and proven medical guidance. Each recovery story reflects our dedication to improving lives through expert, compassionate treatment

0 +

Reviews

With over 100 positive reviews, our patients’ trust speaks for itself. Their feedback reflects our consistent commitment to quality, care, and results.

Get 20% off your First Visit

Get 20% off your first visit — quality care made even more accessible for new patients!